Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc.


Overview | Financials
Company Name Eupraxia Pharmaceuticals Inc.
Symbol EPRX.TO
Currency CAD
Price 4
Market Cap 142,490,400
Dividend Yield 0%
52-week-range 3.44 - 9.1
Industry Biotechnology
Sector Healthcare
CEO Dr. James A. Helliwell FRCPC, M.D.

An error occurred while fetching data.

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis,

Related Stocks

Helix BioPharma Corp. logo

Helix BioPharma Corp.


0.21 CAD

Antibe Therapeutics Inc. logo

Antibe Therapeutics Inc.


0.295 CAD


Numbers are in millions USD

Numbers are in millions USD